Research News
View articles by month and year
11–15 of 15 articles
-
Older Women Do Better on Conventional Chemo Compared to Xeloda
Research shows that women older than 65 do better on standard intravenous chemotherapy after surgery to remove early-stage breast cancer than Xeloda (chemical name: capecitabine), an oral chemotherapy.
-
Taxol Added to Chemo Combination Improved Survival of Women Diagnosed with Early-Stage Breast Cancer
After surgery to treat early-stage breast cancer, women who got Taxol after the FEC (fluorouracil, Ellence, Cytoxan) chemotherapy combination were more likely to be alive and cancer-free 5 years after diagnosis than women who got only FEC.
-
Taxol Weekly Better Than Every Three Weeks for Breast Cancer
Getting Taxol (chemical name: placlitaxel) every week seems to have more benefits than getting it every 3 weeks or getting Taxotere (chemical name: docetaxel) on either schedule.
-
Taxotere Combo Improves Survival
The combination of Taxotere (chemical name: docetaxel) and Cytoxan (chemical name: cyclophosphamide) offers better survival and fewer and less severe side effects than the combination of Adriamycin (chemical name: doxorubicin) and Cytoxan for treating breast cancer.
-
Some Women Don’t Benefit from Adding Taxol to Chemo Regimen
An early breast cancer's HER2 status affects the benefits offered by Taxol.
11–15 of 15 articles
